In Brief: Schmidt Sells OMB On Training Grants, But Weinberger Is The One To Convince

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Benno Schmidt, chairman of the President’s Cancer Panel, feels he made progress when he argued NCI’s case on research training grants and fellowships with Office of Management & Budget. In this instance, however, OMB will not have the last word. HEW Secretary Caspar Weinberger decided, when he headed OMB, to kill the NIH training pro­gram and wouldn’t change his mind after moving to HEW. Congress may have forced Weinberger to back down (See HEW budget story page 2) …. 

NCI Director Frank Rauscher says the most damaging blow to cancer research has been the Administration’s ceiling on posi­tions. NCI scientists are doing clerical work because OMB (or Wein­berger) won’t permit Rauscher to hire more people. Rauscher may put to use the authority he has to bypass HEW and take his case directly to the President, and Congress …. 

Another level of contract review may be superimposed over NIH procedures by HEW. Asst. Secretary for Health Charles Edwards is considering establishing review in his office for contracts over $1 million. Rauscher fears this would add 1-2 months to review time already requiring 5-7 months.

YOU MAY BE INTERESTED IN

The nagging pain in Mia Sandino’s right knee set in in September 2018, and throughout her freshman year at the University of Washington, she tried to ignore it. “I was being a very naive and invincible-feeling 19-year-old,” Sandino told The Cancer Letter. “I didn’t put two and two together that this area of the knee that...

Rick Pazdur, MD, the newly appointed director for the Center for Drug Evaluation and Research at the FDA, has been described as “greyhound thin” as a result of his dedication to cycling and lifting weights in the gym each day and, for a long time, a vegetarian diet. I first met him when he was the director of the Office of Oncology Drug Products (ODP) within CDER, in 2009.
When it comes to fighting cancer today, collaboration is key. At a time when funding is uncertain, yet innovative breakthroughs are accelerating every day, it’s more important than ever for oncologists, scientists, academic researchers, and community physicians, to come together to share knowledge and gain insights about the forefront of cancer research.

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login